Pharmaceutical

Dizal receives approval in China for NSCLC therapy

Dizal has received approval from China’s NMPA for sunvozertinib to treat adult patients with locally advanced or metastatic NSCLC

Aug 24, 2023 - 20:00
Dizal receives approval in China for NSCLC therapy
Dizal has received approval from China’s NMPA for sunvozertinib to treat adult patients with locally advanced or metastatic NSCLC
Read the original article

Tags:

Previous Article

Japan grants patent for BioArctic’s Parkinson’s disease antibody

Next Article

Spanish pharmaceutical company Serra Pamies faces EMA production restrictions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: To prevent amputation in patients with severe vascular disease, a device turns veins into arteries

STAT+: To prevent amputation in patients with severe va...

Oct 4, 2023

STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya

STAT+: Pharmalittle: Novo Nordisk to spend $6 billion t...

Nov 11, 2023

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023